adefovir dipivoxil + nelfinavir + nucleoside reverse transcriptase inhibitor

This is a multi-drug combination consisting of **adefovir dipivoxil** (a nucleotide reverse transcriptase inhibitor), **nelfinavir** (a protease inhibitor), and a **nucleoside reverse transcriptase inhibitor** (NRTI; unspecified, but commonly refers to drugs such as zidovudine, lamivudine, abacavir, etc.), used in the management of **HIV-1 infection** in cases of virological failure or as part of highly active antiretroviral therapy (HAART). - **Adefovir dipivoxil** inhibits HIV reverse transcriptase by acting as a nucleotide analogue, impeding viral DNA synthesis[1]. - **Nelfinavir** inhibits the HIV-1 protease, preventing the cleavage of viral polyproteins and thus halting viral maturation[2][6]. - **Nucleoside reverse transcriptase inhibitors** act via incorporation into viral DNA, causing chain termination. This combination, or similar variants, has been studied in clinical trials for treatment-experienced individuals with HIV-1 infection experiencing virological failure[3][5]. Renal toxicity is a significant concern for adefovir dipivoxil, and nelfinavir is associated with metabolic adverse effects[1][2][6].